VidaMed wins TUNA (transurethral needle ablation) court battle with ProSurg:
This article was originally published in Clinica
A US District Court has granted VidaMed's motion for summary judgment against ProSurg for "asking, encouraging or otherwise soliciting physicians to use ProSurg's Opal and Opal Flex products to treat BPH (benign prostatic hyperplasia)." The court found that VidaMed's patent 5,536,240 covering the use of radiofrequency electrodes for treatment of BPH, known as transurethral needle ablation (TUNA), was infringed. VidaMed of Freemont, California, says the decision strengthens its case in ongoing litigation between the two companies.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.